Engineered nanovesicles as a DC vaccine to enhance the antitumor efficacy of CAR-T cells against solid tumors - PubMed
a day ago
- #Nanovesicles
- #Lung cancer
- #CAR-T therapy
- Engineered CD205-targeted nanovesicles (aCD205 NVs) derived from LLC cells enhance dendritic cell (DC) targeting and maturation.
- Combination therapy (CAR-T + Vac) significantly increases tumor infiltration of CAR-T cells and endogenous T cells in lung cancer models.
- The therapy elevates cytotoxic molecules (Granzyme B, Perforin) and pro-inflammatory cytokines (IFN-γ, TNF-α) while reducing immunosuppressive cells (M2 macrophages, MDSCs, Tregs).
- CAR-T + Vac therapy results in potent tumor suppression and prolonged survival with no short-term toxicity observed.
- The study provides a promising platform for advancing immunotherapy against solid tumors by reprogramming the immunosuppressive tumor microenvironment.